Neuraly, Inc. is a biotechnology company focused on developing immunotherapies for neurodegenerative diseases, with a primary focus on Parkinson's disease (PD) and Alzheimer's disease (AD). The company's lead candidate, NLY01 (also known as Pegcreatecan), is a novel glucagon-like peptide-1 receptor (GLP-1R) agonist designed to target neuroinflammation and alpha-synuclein pathology[1][2].
| Attribute | Details |
|---|---|
| Headquarters | Gaithersburg, Maryland, USA |
| Founded | 2016 |
| Ticker | Private |
| Focus | Neurodegenerative disease immunotherapies |
| Website | neuralyinc.com |
Neuraly's platform is based on targeting neuroinflammation through GLP-1 receptor modulation. The company developed NLY01 as a long-acting GLP-1R agonist that penetrates the blood-brain barrier to exert neuroprotective effects[2:1].
NLY01 works through multiple pathways:
| Attribute | Details |
|---|---|
| Target | GLP-1 receptor, neuroinflammation |
| Indication | Parkinson's Disease |
| Mechanism | GLP-1R agonist with anti-inflammatory properties |
| Status | Phase 2 clinical development |
| Administration | Subcutaneous injection |
NLY01 completed Phase 1 trials demonstrating safety and tolerability in healthy volunteers and patients with Parkinson's disease[3].
The company advanced NLY01 into Phase 2 clinical trials for Parkinson's disease to evaluate efficacy and safety. The trial aimed to assess motor symptoms, cognitive function, and biomarkers of neuroinflammation[2:2].
Beyond Parkinson's disease, NLY01 may have applications in:
Preclinical studies demonstrated that NLY01:
The development of NLY01 is part of a broader therapeutic approach using GLP-1 receptor agonists for neuroprotection. Other companies developing similar approaches include:
| Company | Drug | Mechanism | Stage |
|---|---|---|---|
| Prothena | Prasinezumab | Anti-α-syn mAb | Phase 2 |
| Biogen | BIIB122 | LRRK2 inhibitor | Phase 2b |
| Denali Therapeutics | DNL151 | LRRK2 inhibitor | Phase 2b |
| Novartis | Cinpanemab | Anti-α-syn mAb | Phase 2 |
| Roche | Prasinezumab | Anti-α-syn mAb | Phase 2 |
Neuraly has received funding from venture capital investors to support its clinical development programs. The company operates as a private entity and may seek additional financing or partnership opportunities to advance its pipeline[1:2].
Neuraly Inc. Company Website. ↩︎ ↩︎ ↩︎
Neuraly Scientific Pipeline. Neuraly NLY01 Program. ↩︎ ↩︎ ↩︎
GLP-1 receptor agonists for neurodegenerative diseases. Science Translational Medicine. ↩︎